Comparative Pharmacology
Head-to-head clinical analysis: FUROSCIX versus LASIX ONYU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUROSCIX versus LASIX ONYU.
FUROSCIX vs LASIX ONYU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
Lasix (furosemide) inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption.
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
Furosemide 20-80 mg IV/PO once or twice daily; max 600 mg/day for IV, 80 mg/day for PO.
None Documented
None Documented
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (CrCl <30 mL/min) and 9-19 hours in anuria
1.5-2.0 hours in normal renal function; prolonged to 10-15 hours in severe renal impairment (CrCl <10 mL/min); clinically significant accumulation risk with repeated dosing in renal disease.
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Primarily renal (50-80% as unchanged drug); biliary/fecal (20-30%); non-renal clearance accounts for up to 20%.
Category C
Category C
Loop Diuretic
Loop Diuretic